MapmyIndia IPO Subscription Status, GMP, Valuation. Last Day to Invest, Should you?
MapmyIndia IPO subscribed 154.7 times on final day
MapmyIndia IPO subscribed 154.7 times on final day
On the third and final day of the bidding process, the Rs-crore original public offer (IPO) of CE Info Systems (MapmyIndia) is witnessing a strong response from investors. The issue was subscribed154.7 times at 500 pm on Friday, thanks to strong buying from all orders of investors.
On the third and final day of the bidding process, the Rs-crore original public offer (IPO) of CE Info Systems (MapmyIndia) is witnessing a strong response from investors.
The issue was subscribed154.7 times at 500 pm on Friday, thanks to strong buying from all orders of investors. It saw operations for shares against the issue size of shares, the data from BSE suggested.
The issue, with a price band of Rs-, opened for public.
Proceeds of the fresh issue will be used towards payment of debt and for general commercial purposes.
Emcure Pharmaceuticals is engaged in developing, manufacturing and encyclopedically selling a broad range of pharmaceutical products across several major remedial areas. The company has presence in 70 requests encyclopedically.
The Pune- grounded company is presently developing RNA vaccine for COVID-19 through its attachment, Gennova Biopharmaceuticals.
Axis Capital, JM Financial.
Proceeds of the fresh issue will be used towards payment of debt and for general commercial purposes.
Emcure Pharmaceuticals is engaged in developing, manufacturing and encyclopedically selling a broad range of pharmaceutical products across several major remedial areas. The company has presence in 70 requests encyclopedically.
The Pune- grounded company is presently developing RNA vaccine for COVID-19 through its attachment, Gennova Biopharmaceuticals.
Axis Capital, JM Financial.
MAPMYINDIA GMP
Rearmost information suggests that the MapmyIndia IPO GMP is Rs or over 98 per cent to its issue price of Rs. This means the stock will list at roughly Rs if the GMP doesn’t fall.
It may be noted that the GMP only gives an suggestion of how a company is anticipated to list on the stock exchanges. Still, the GMP does suggest that the stock is in for a cushion listing on the BSE and NSE.
As mentioned before, several brokerages had given a‘ subscribe’ standing to the IPO, due to the company’s strong fiscal position, profitable business model and strong cash overflows.
Brokerage Anand Rathi said in a note that MapMyIndia is all set to subsidize on the exponential growth occasion of being the request leader, adding that it also has an early transport advantage and a profitable business model with a harmonious fiscal track record and strong cash inflow.
